A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects With Schizophrenia.
Phase of Trial: Phase III
Latest Information Update: 12 Aug 2014
At a glance
- Drugs Paliperidone (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 03 Feb 2012 Actual patient number changed from 1221 to 1220 as reported by ClinicalTrials.gov.
- 14 Sep 2010 US FDA approved NDA for paliperidone for the acute and maintenance treatment of schizophrenia based data from this and other pivotal trials.
- 06 Jun 2010 Results have been presented at the 27th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History